Effect of fluvastatin on ischaemia following acute myocardial infarction: A randomized trial

European Heart Journal

Volumn 23, Issue 24, 2002, Pages 1931-1937

  Liem, A H ^a   Van Boven, A J ^b   Veeger, N J G M ^b   Withagen, A J ^c   Robles de Medina, R M ^d   Tijssens, J G P ^e   Van Veldhuisen, D J ^a,b  

^a Stichting Oosterschelde Ziekenhuizen   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c REINIER DE GRAAF HOSPITAL   (Netherlands)

^d LEYENBURG HOSPITAL   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Acute coronary syndrome; Ambulatory electrocardiographic monitoring; Fluvastatin; Myocardial ischaemia; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; AGED; AMBULATORY MONITORING; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMAN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPOPROTEINS, LDL CHOLESTEROL; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; SUPPORT, NON-U.S. GOV'T;

EID: 0036899472     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2002.3291     Document Type: Article

References (22)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57.
4. Deedwania PC, Carbajal EV. Ambulatory electrocardiography evaluation of asymptomatic, unstable, and stable coronary artery disease patients for myocardial ischemia. Cardiol Clin 1992; 10: 417-30.
5. Sharaf BL, Williams DO, Miele NJ et al. A detailed angiographic analysis of patients with ambulatory electrocardiographic ischemia: Results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) study angiographic core laboratory. J Am Coll Cardiol 1997; 29: 78-84.
6. Ouyang P, Chandra NC, Gottlieb SO. Frequency and importance of silent myocardial ischemia identified with ambulatory electrocardiographic monitoring in the early in-hospital period after acute myocardial infarction. Am J Cardiol 1990; 65: 267-70.
7. Langer A, Minkowitz J, Dorian P et al. Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group. J Am Coll Cardiol 1992; 20: 1313-7.
8. Solimene MC, Ramires JA, Gruppi CJ et al. Prognostic significance of silent myocardial ischemia after a first uncomplicated myocardial infarction. Int J Cardiol 1993; 38: 41-7.
9. Silva P, Galli M, Campolo L. Prognostic significance of early ischemia after acute myocardial infarction in low-risk patients. IRES (Ischemia Residua) Study Group. Am J Cardiol 1993; 71: 1142-7.
10. Gill JB, Cairns JA, Roberts RS et al. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med 1996; 334: 65-70.
11. Andrews TC, Raby K, Barry J et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-8.
12. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation 1996; 94: 1503-5.
13. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
14. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-402.
15. Yokoyama I, Momomura S, Ohtake T et al. Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. Circulation 1999; 100: 117-22.
16. Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999; 99: 475-81.
17. Rogers WJ, Bourassa MG, Andrews TC et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: Outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators. J Am Coll Cardiol 1995; 26: 594-605.
18. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995-1001.
19. Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol 2000; 85 (Suppl 3A): 10A-7A.
20. Aronow HD, Topol EJ, Roe MT et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet 2001; 357: 1063-8.
21. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD, on behalf of the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52.
22. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-8.